Understanding Influenza Neuraminidase Inhibitors Using Quantitative Structure-Activity Relationship (QSAR) Models

Combating the Threat of Pandemic Influenza: Drug Discovery Approaches

Volumn , Issue , 2007, Pages 209-225

  Verma, Rajeshwar P ^a   Hansch, Corwin ^a  

^a POMONA COLLEGE   (United States)

Author keywords

NA inhibitors in treating influenza infection; QSAR model validation; Understanding influenza neuraminidase inhibitors

Indexed keywords

EID: 80053431963     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470179727.ch9     Document Type: Chapter

References (33)

1. Thompson, W. W.; Shay, D. K.; Weintraub, E.; Brammer, L.; Cox, N.; Anderson, L. J.; Fukuda, K. Mortality associated with influenza and respiratory syncytial virus in the United States. J. Am. Med. Assoc. 2003, 289, 179-186.
2. Carey, M. A.; Bradbury, J. A.; Seubert, J. M.; Langenbach, R.; Zeldin, D. C.; Germolec, D. R. Contrasting effects of cyclooxygenase-1 (COX-1) and COX-2 deficiency on the host response to influenza A viral infection. J. Immunol. 2005, 175, 6878-6884.
3. Nicholson, K. G.; Wood, J. M.; Zambon, M. Influenza. Lancet 2003, 362, 1733-1745.
4. Kim, C. U.; Lew, W.; Williams, M. A.; Zhang, L.; Liu, H.; Swaminathan, S.; Bischofberger, N.; Chen, M. S.; Tai, C. Y.; Mendel, D. B.; Laver, W. G.; Stevens, R. C. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogs with potent anti-influenza activity. J. Am. Chem. Soc. 1997, 119, 681-690.
5. Smith, P. W.; Sollis, S. L.; Howes, P. D.; Cherry, P. C.; Starkey, I. D.; Cobley, K. N.; Weston, H.; Scicinski, J.; Merritt, A.; Whittington, A.; Wyatt, P.; Taylor, N.; Green, D.; Bethell, R.; Madar, S.; Fenton, R. J.; Morley, P. J.; Pateman, T.; Beresford, A. Dihydropyrancarboxamides related to zanami-vir: a new series of inhibitors of influenza virus sialidases. 1. Discovery, synthesis, biological activity, and structure-activity relationships of 4-gua-nidino-and 4-amino-4#-pyran-6-carboxamides. J. Med. Chem. 1998, 41, 787-797.
6. Chand, P.; Babu, Y. S.; Bantia, S.; Rowland, S.; Dehghani, A.; Kotian, P. L.; Hutchison, T. L.; Ali, S.; Brouillette, W.; El-Kattan, Y.; Lin, T.-H. Syntheses and neuraminidase inhibitory activity of multisubstituted cyclopentane amide derivatives. J. Med. Chem. 2004, 47, 1919-1929.
7. Verma, R. P.; Hansch, C. A QSAR study on influenza neuraminidase inhibitors. Bioorg. Med. Chem. 2006, 14, 982-996.
8. Hansch, C.; Maloney, P. P.; Fujita, T.; Muir, R. M. Correlation of biological activity of phenoxyacetic acids with Hammett substituent constants and partition coefficients. Nature 1962, 194, 178-180.
9. Hansch, C.; Leo, A. In Exploring QSAR: Fundamentals and Applications in Chemistry and Biology, American Chemical Society, Washington, D.C., 1995.
10. Selassie, C.D.; Garg, R.; Kapur, S.; Kurup, A.; Verma, R. P.; Mekapati, S. B.; Hansch, C. Comparative QSAR and the radical toxicity of various functional groups. Chem. Rev. 2002, 102, 2585-2605.
11. Verma, R. P.; Kurup, A.; Mekapati, S. B.; Hansch, C. Chemical-biological interactions in human. Bioorg. Med. Chem. 2005, 13, 933-948.
12. Hansch, C.; Leo, A.; Mekapati, S. B.; Kurup, A. QSAR and AD ME. Bioorg. Med. Chem. 2004, 12, 3391-3400.
13. Selassie, C. D.; Mekapati, S. B.; Verma, R. P. QSAR: Then and now. Curr. Top. Med. Chem. 2002, 2, 1357-1379.
14. C-QSAR Program, BioByte Corp., 201W. 4th Street, Suite 204, Claremont, CA 91711, USA, www.biobyte.com.
15. Cramer, R. D., III; Bunce, J. D.; Patterson, D. E.; Frank, I. E. Cross validation, Bootstrapping and partial least squares compared with multiple regression in conventional QSAR studies. Quant. Struct.-Act. Relat. 1988, 7, 18-25.
16. Pogliani, L. Modeling with special descriptors derived from a mediumsized set of connectivity indices. J. Phys. Chem. 1996, 100, 18065-18077.
17. Pogliani, L. From molecular connectivity indices to semiempirical connectivity terms: Recent trends in graph theoretical descriptors. Chem. Rev. 2000, 100, 3827-3858.
18. Agrawal, V.; Singh, J.; Khadikar, P. V.; Supuran, C. T. QSAR study on topically acting sulfonamides incorporating GABA moieties: A molecular connectivity approach. Bioorg. Med. Chem. Lett. 2006, 16, 2044-2051.
19. Selassie, C. D.; Kapur, S.; Verma, R. P.; Rosario, M. Cellular apoptosis and cytotoxicity of phenolic compounds: a quantitative structure-activity relationship study. J. Med. Chem. 2005, 48, 7234-7242.
20. Verma, R. P.; Hansch, C. Cytotoxicity of organic compounds against ovarian cancer cells: A quantitative structure-activity relationship study. Mol. Pharm. 2006, 3, 441-450.
21. Verma, R. P.; Hansch, C. Understanding human rhinovirus infections in terms of QSAR. Virology 2007, 359, 152-161.
22. Lew, W.; Wu, H.; Chen, X.; Graves, B. J.; Escarpe, P. A.; MacArthur, H. L.; Mendel, D. B.; Kim, C. U. Carbocyclic influenza neuraminidase inhibitors possessing a C_inf_3_/inf_-cyclic amine side chain: Synthesis and inhibitory activity. Bioorg. Med. Chem. Lett. 2000, 10, 1257-1260.
23. Kim, C. U.; Lew, W.; Williams, M. A.; Wu, H.; Zhang, L.; Chen, X.; Escarpe, P. A.; Mendel, D. B.; Laver, W. G.; Stevens, R. C. Structure-activity relationship studies of novel carbocyclic influenza neuraminidase inhibitors. J. Med. Chem. 1998, 41, 2451-2460.
24. Lew, W.; Wu, H.; Mendel, D. B.; Escarpe, P. A.; Chen, X.; Laver, W. G.; Graves, B. J.; Kim, C. U. A new series of C_inf_3_/inf_-aza carbocyclic influenza neuraminidase inhibitors: Synthesis and inhibitory activity. Bioorg. Med. Chem. Lett. 1998, 8, 3321-3324.
25. Williams, M.A.; Lew, W.; Mendel, D.B.; Tai, C. Y.; Escarpe, P. A.; Laver, W. G.; Stevens, R. C.; Kim, C. U. Structure-activity relationships of carbocyclic influenza neuraminidase inhibitors. Bioorg. Med. Chem. Lett. 1997, 7, 1837-1842.
26. Lew, W; Williams, M. A.; Mendel, D. B.; Escarpe, P. A., Kim, C. U. C_inf_3_/inf_-thia and C3-carba isosteres of a carbocyclic influenza neuraminidase inhibitor, (3R, 4R, 5S)-4-acetamido-5-amino-3-propoxy-1-cyclohexene-1-carboxylic acid. Bioorg. Med. Chem. Lett. 1997, 7, 1843-1846.
27. Golbraikh, A.; Tropsha, A. Beware of q_sup_2_/sup_! J. Mol. Graph. Modl. 2002, 20, 269-276.
28. Tropsha, A.; Gramatica, P.; Gombar, V. K. The importance of being earnest: Validation is the absolute essential for successful application and interpretation of QSPR models. QSAR Comb. Sci. 2003, 22, 69-77.
29. Spartan'06Program, Wavefunction, Inc., 18401 VonKarmanAvenue, Suite 370, Irvine, CA 92612, USA. www.wavefun.com.
30. Freitas, M. P. MIA-QSAR modelling of anti-HIV-1 acvtivities of some 2-amino-6-arylsulfonylbenzonitriles and their thio and sulfinyl congeners. Org. Biomol. Chem. 2006, 4, 1154-1159.
31. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug. Delivery Rev. 1997, 23, 3-25.
32. Kubinyi, H. Drug research: Myths, hype and reality. Nature Rev. 2003, 2, 665-668.
33. Clark, D. E. Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 1. Prediction of intestinal absorption. J. Pharm. Sci. 1999, 88, 807-814.